prescription drug plans and private payors employ under such programs to support the efforts of pharmacies. (3) How such programs compare for Medicare prescription drug plans and private payors. (4) What is known about how such programs affect patient medication adherence and overall patient health outcomes and health outcomes, including if adherence and outcomes vary by patient subpopulations, such as disease state and socioeconomic status. (5) What is known about overall patient satisfaction with such programs and satisfaction with such programs, including within patient subpopulations, such as disease state and socioeconomic status. (6) The extent to which laws and regulations of the Medicare program support such programs. (7) Barriers to the use of medication synchronization programs by Medicare prescription drug plans. (b) Report Not later than 18 months after the date of the enactment of this Act, the Comptroller General shall submit to Congress a report containing the results of the study under subsection (a), together with recommendations for such legislation and administrative action as the Comptroller General determines appropriate. 602. GAO study and report on impact of obesity drugs on patient health and spending (a) Study The Comptroller General of the United States (in this section referred to as the Comptroller General ) shall conduct a study on the use of prescription drugs to manage the weight of obese patients and the impact of coverage of such drugs on patient health and on health care spending. Such study shall examine the use and impact of these obesity drugs in the non-Medicare population and for Medicare beneficiaries who have such drugs covered through an MA–PD plan (as defined in section 1860D–1(a)(3)(C) of the Social Security Act ( 42 U.S.C. 1395w–101(a)(3)(C) )) as a supplemental health care benefit. The study shall include an analysis of the following: (1) The prevalence of obesity in the Medicare and non-Medicare population. (2) The utilization of obesity drugs. (3) The distribution